• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Renovacor Inc.

    12/1/22 5:14:29 PM ET
    $RCOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCOR alert in real time by email
    POS AM 1 brhc10044891_posam.htm POS AM
    As filed with the Securities and Exchange Commission on December 1, 2022.
    Registration No. 333-236977
    Registration No. 333-260299

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    POST-EFFECTIVE AMENDMENT NO. 1 TO
    Form S-1 Registration No. 333-236977
    Form S-1 Registration No. 333-260299
    UNDER THE SECURITIES ACT OF 1933



    Renovacor, Inc.
    (ZEBRAFISH MERGER SUB II, LLC, AS SUCCESSOR TO RENOVACOR, INC.)
    (Exact name of registrant as specified in its charter)



    Delaware
    2836
    83-3169838
    (State or other jurisdiction of incorporation or organization)
    (Primary Standard Industrial Classification Code Number)
    (I.R.S. Employer Identification Number)
     
    201 Broadway, Suite 310
    Cambridge, Massachusetts 02139
    (610) 424-2650
    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)



     
     
    Copies to:
    Magdalene Cook, M.D.
    President and Chief Executive Officer
    201 Broadway, Suite 310
    Cambridge, Massachusetts 02139
    (610) 424-2650
     
    John T. Haggerty
    William D. Collins
    Sarah Ashfaq
    Goodwin Procter LLP
    100 Northern Avenue
    Boston, Massachusetts 02210
    (617) 570-1000

    (Name, address and telephone number of agent for service)


     
    Approximate date of commencement of proposed sale to the public: This post-effective amendment is being filed to deregister all of the unsold securities previously registered under the Registration Statements.
     
    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒
     
    If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
     
    If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
     
    If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐
    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒




    Emerging growth company

    ☒
     


    DEREGISTRATION OF SECURITIES
     
    This Post-Effective Amendment No. 1 relates to the Registration Statements on Form S-1 (each a “Registration Statement,” and collectively, the “Registration Statements”), filed with the Securities Exchange Commission (the “SEC”) by Renovacor, Inc. (the “Registrant”):


    •
    Registration Statement No. 333-236977, as amended, originally filed with the SEC on March 9, 2020, pertaining to the registration of an aggregate of 9,775,000 Units each consisting of one share of common stock, par value $0.0001 per share, and one Warrant entitling the holder to purchase one-half of a share of common stock, 9,775,000 shares of common stock, par value $0.0001 per share, and 9,775,000 Warrants included as part of the units; and


    •
    Registration Statement No. 333-260299, filed with the SEC on October 15, 2021, pertaining to the registration of an aggregate of 7,811,322 shares of common stock, par value $0.0001 per share, issuable upon the exercise of the Public Warrants and Private Placement Warrants, 715,224 shares of common stock, par value $0.0001 per share, issuable upon the exercise of the Pre-Funded Warrants, 12,668,314 shares of common stock, par value $0.0001 per share, and 3,500,000 Private Placement Warrants to purchase common stock.

    The Company is filing this Post-Effective Amendment No. 1 to the Registration Statements to deregister any and all securities that remain unsold under the Registration Statements as of the date hereof.

    On December 1, 2022, pursuant to the terms of an Agreement and Plan of Merger (the “Merger Agreement”), dated as of September 19, 2022, by and among the Registrant, Rocket Pharmaceuticals, Inc. (“Rocket”), a Delaware corporation, Zebrafish Merger Sub, Inc. (“Merger Sub I”), a Delaware corporation and a direct wholly owned subsidiary of Rocket, and Zebrafish Merger Sub II, LLC (“Merger Sub II”), a Delaware limited liability company and a direct wholly owned subsidiary of Rocket, (i) Merger Sub I merged with and into the Registrant (the “First Merger”) and (ii) the Registrant, as the surviving company of the First Merger, merged with and into Merger Sub II (the “Second Merger” and together with the First Merger, the “Mergers”), with Merger Sub II as the surviving company and successor-in-interest to the Registrant following the Mergers, at which time the separate corporate existence of the Registrant ended.

    As a result of the Mergers, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unissued at the termination of the offerings, the Registrant hereby removes from registration all securities registered but unsold under such Registration Statements, if any, as of the date hereof


    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this Post-Effective Amendment to the Registration Statements on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts on this 1st day of December, 2022.
     

    Zebrafish Merger Sub II, LLC

    (as successor by merger to Renovacor, Inc.)




    By:
    /s/ Gaurav Shah

    Name:
    Gaurav Shah

    Title:
    Authorized Person

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933.
     


    Get the next $RCOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCOR

    DatePrice TargetRatingAnalyst
    9/13/2022$9.00Outperform
    Robert W. Baird
    10/14/2021$22.00Buy
    Ladenburg Thalmann
    10/1/2021$20.00Buy
    Chardan Capital Markets
    More analyst ratings

    $RCOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Renovacor with a new price target

      Robert W. Baird initiated coverage of Renovacor with a rating of Outperform and set a new price target of $9.00

      9/13/22 7:37:19 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Renovacor with a new price target

      Ladenburg Thalmann initiated coverage of Renovacor with a rating of Buy and set a new price target of $22.00

      10/14/21 7:14:33 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Renovacor with a new price target

      Chardan Capital Markets initiated coverage of Renovacor with a rating of Buy and set a new price target of $20.00

      10/1/21 7:39:25 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Renovacor Inc.

      15-12G - Renovacor, Inc. (0001799850) (Filer)

      12/12/22 4:35:37 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Renovacor Inc.

      EFFECT - Renovacor, Inc. (0001799850) (Filer)

      12/6/22 12:15:05 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Renovacor Inc.

      EFFECT - Renovacor, Inc. (0001799850) (Filer)

      12/6/22 12:15:13 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Renovacor Inc. (Amendment)

      SC 13D/A - Renovacor, Inc. (0001799850) (Subject)

      4/5/23 4:31:54 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Renovacor Inc. (Amendment)

      SC 13G/A - Renovacor, Inc. (0001799850) (Subject)

      2/14/23 7:41:31 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Renovacor Inc.

      SC 13D - Renovacor, Inc. (0001799850) (Subject)

      9/21/22 9:00:09 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovacor Announces the Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations

      Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies Renovacor, Inc. (NYSE:RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations. "With Kumar's appointment, we've added yet another innovative industry expert to Renovacor's diverse and growing leadership team," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor. "Kumar is

      10/4/21 4:05:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science

      Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice Renovacor, Inc. (NYSE:RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science. "We are excited to welcome Jordan to Renovacor's leadership team during this pivotal time for the company," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor.

      9/22/21 4:05:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Rtw Investments, Lp

      4 - Renovacor, Inc. (0001799850) (Issuer)

      4/5/23 4:30:43 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Needham Thomas E. Jr.

      4 - Renovacor, Inc. (0001799850) (Issuer)

      12/5/22 9:24:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lau Joan

      4 - Renovacor, Inc. (0001799850) (Issuer)

      12/5/22 9:23:45 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Completes Acquisition of Renovacor

      Acquisition further extends Rocket's leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Under the terms of t

      12/1/22 4:01:00 PM ET
      $RCKT
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

      Acquisition further strengthens Rocket's leadership in AAV-based cardiac gene therapy and expands Company's near-term clinical assets for the treatment of heart conditions Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 di

      9/20/22 6:00:00 AM ET
      $RCKT
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care